Related Experiment Video

Updated: Apr 30, 2026

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
08:28

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Published on: February 15, 2022

3.2K

Activation of AMPK inhibits pulmonary arterial smooth muscle cells proliferation

Yuanyuan Wu1, Lu Liu, Yonghong Zhang

  • 1Department of Respiratory Medicine, Respiratory Diseases Research Center, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.

Experimental Lung Research
|May 10, 2014
PubMed

Insights

Metformin, an AMPK activator, inhibits pulmonary arterial smooth muscle cell proliferation by modulating Skp2 and p27 levels. This finding suggests potential therapeutic applications for pulmonary arterial hypertension (PAH).

Area of Science:

  • Cardiovascular Biology
  • Cellular Physiology
  • Pharmacology

Background:

  • Pulmonary arterial hypertension (PAH) involves abnormal proliferation of pulmonary arterial smooth muscle cells (PASMCs).
  • Endothelin-1 (ET-1) is a key mediator in the pathogenesis of PAH, stimulating PASMC proliferation.
  • Understanding the molecular mechanisms regulating PASMC proliferation is crucial for developing effective PAH treatments.

Purpose of the Study:

  • To investigate the impact of AMP-activated protein kinase (AMPK) activation on PASMC proliferation.
  • To elucidate the underlying molecular mechanisms by which AMPK influences PASMC growth.
  • To evaluate the potential of AMPK activation as a therapeutic strategy for PAH.

Main Methods:

  • Primary human PASMCs were cultured and treated with ET-1 and metformin (an AMPK activator).
  • Cell proliferation was assessed using standard assays.
  • Protein levels of Skp2 and p27 were analyzed by Western blotting.

Main Results:

  • ET-1 dose- and time-dependently increased PASMC proliferation.
  • Metformin significantly suppressed ET-1-induced PASMC proliferation.
  • Metformin reversed the ET-1-mediated increase in Skp2 and decrease in p27 protein levels.

Conclusions:

  • AMPK activation effectively suppresses PASMC proliferation.
  • The mechanism involves the regulation of Skp2 and p27 protein expression.
  • Targeting AMPK activation may offer a novel therapeutic approach for preventing or treating pulmonary vascular remodeling in PAH.

More Related Videos

Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses07:56

Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses

Published on: June 8, 2022

4.3K
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice08:02

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Published on: October 19, 2013

18.0K

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K